Intermediate conductance calcium-activated potassium channel protein 4 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Intermediate conductance calcium-activated potassium channel protein 4 shows late clinical disease relevance led by sickle cell anemia. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O15554. Start with sickle cell anemia, then reuse UniProt O15554 as the stable protein anchor across project notes and exports.
Start with sickle cell anemia, then reuse UniProt O15554 as the stable protein anchor across project notes and exports.
Intermediate conductance calcium-activated potassium channel protein 4 shows late clinical disease relevance led by sickle cell anemia. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with sickle cell anemia because it currently carries late clinical support. Linked drugs include SENICAPOC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyIntermediate conductance calcium-activated potassium channel protein 4
Review this target as Intermediate conductance calcium-activated potassium channel protein 4, mapped to UniProt O15554. Sequence length is 427 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Intermediate conductance calcium-activated potassium channel protein 4 as ChEMBL target CHEMBL4305, mapped to UniProt O15554. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Intermediate conductance calcium-activated potassium channel protein 4 is the right protein anchor across sources, using UniProt O15554 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why sickle cell anemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Intermediate conductance calcium-activated potassium channel protein 4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O15554 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Intermediate conductance calcium-activated potassium channel protein 4 |
| UniProt Accession | O15554 |
| Component Type | Protein |
| Sequence Length | 427 aa |
Intermediate conductance calcium-activated potassium channel protein 4
Review this target as Intermediate conductance calcium-activated potassium channel protein 4, mapped to UniProt O15554. Sequence length is 427 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Intermediate conductance calcium-activated potassium channel protein 4 shows late clinical disease relevance led by sickle cell anemia. 3 more disease programs remain visible in the same review block.
Start review with sickle cell anemia because it currently carries late clinical support. Linked drugs include SENICAPOC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL405821 | 8.22 | IC50 | 6.0 | Clinical |
| CHEMBL4744833 | 8.09 | IC50 | 8.1 | Preclinical |
| CHEMBL4749039 | 8.07 | IC50 | 8.6 | Preclinical |
| CHEMBL4791725 | 8.06 | IC50 | 8.7 | Preclinical |
| CHEMBL42205 | 8.05 | IC50 | 9.0 | Preclinical |
| CHEMBL272039 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL260736 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL270704 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL272040 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL4788143 | 7.85 | IC50 | 14.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 9 | 26 | 7.0 |
| single protein format | 7 | 38 | 6.5 |
| assay format | 4 | 111 | 6.6 |